Aldolase a in pan-cancer and lung squamous cell carcinoma: prognostic value and macrophage-driven immune suppression unveiled by multi-omics and cohort validation.

ABSTRACT:

Background

Aldolase A (ALDOA), a key glycolytic enzyme, has been implicated in tumor progression and metabolic reprogramming across multiple cancers [1]. However, its role in lung squamous cell carcinoma (LUSC) remains largely unexplored. Recent studies suggest that ALDOA may influence the tumor immune microenvironment, particularly through its association with macrophages [2, 3]. This study aims to investigate the prognostic value of ALDOA in LUSC and its role in macrophage-mediated immune suppression.

Methods

We conducted a comprehensive pan-cancer analysis to evaluate ALDOA expression, genomic alterations, and prognostic relevance across different cancer types. In LUSC, we validated its prognostic value using immunohistochemical (IHC) staining and independent patient coho

SUBMITTER: Ji Y 

PROVIDER: S-EPMC12619220 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature